A Multi-centre, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multiple Oral Dose Titration Study in Patients With Parkinson's Disease to Assess the Efficacy of AFQ056 in Reducing L-dopa Induced Dyskinesias, and the Safety and Tolerability of AFQ056 in Combination With L-dopa

Trial Profile

A Multi-centre, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multiple Oral Dose Titration Study in Patients With Parkinson's Disease to Assess the Efficacy of AFQ056 in Reducing L-dopa Induced Dyskinesias, and the Safety and Tolerability of AFQ056 in Combination With L-dopa

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Mavoglurant (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 11 Apr 2011 Results published in the Movement Disorders.
    • 22 Jul 2010 Planned end date changed to .
    • 22 Jul 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top